CA1040533A - Controlled gastric residence medicament formulation - Google Patents

Controlled gastric residence medicament formulation

Info

Publication number
CA1040533A
CA1040533A CA173,291A CA173291A CA1040533A CA 1040533 A CA1040533 A CA 1040533A CA 173291 A CA173291 A CA 173291A CA 1040533 A CA1040533 A CA 1040533A
Authority
CA
Canada
Prior art keywords
cross
parts
weight
formulation according
prepolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA173,291A
Other languages
English (en)
French (fr)
Inventor
Gilbert S. Banker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of CA1040533A publication Critical patent/CA1040533A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA173,291A 1972-06-09 1973-06-06 Controlled gastric residence medicament formulation Expired CA1040533A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26124272A 1972-06-09 1972-06-09

Publications (1)

Publication Number Publication Date
CA1040533A true CA1040533A (en) 1978-10-17

Family

ID=22992462

Family Applications (1)

Application Number Title Priority Date Filing Date
CA173,291A Expired CA1040533A (en) 1972-06-09 1973-06-06 Controlled gastric residence medicament formulation

Country Status (19)

Country Link
JP (1) JPS4961323A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU5682673A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE800637A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1040533A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH582002A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (2) DD109309A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2328580A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES415624A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2187290B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1428426A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU167947B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE38151B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL42459A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL7307737A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA04931A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL90109B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO64146A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE395609B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA733897B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421178B2 (en) 2011-12-02 2016-08-23 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207890A (en) 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
JPS5911563B2 (ja) * 1980-02-27 1984-03-16 日本原子力研究所 多層構造の徐放性複合体を製造する方法
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
US4657784A (en) * 1986-03-10 1987-04-14 Ecolab Inc. Process for encapsulating particles with at least two coating layers having different melting points
EP0265061B1 (en) * 1986-09-18 1992-01-08 London School of Pharmacy Innovations Ltd Pharmaceutical formulation
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
EP0327295A3 (en) * 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Tetracycline dosage form
AU614328B2 (en) * 1988-02-01 1991-08-29 Mayne Pharma International Pty Ltd Tetracycline dosage form
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES335314A1 (es) * 1966-01-06 1967-12-01 Ceskoslovenska Akademie Ved Mejoras introducidas en la preparacion de vehiculos insolubles de sustancias al menos parcialmente solubles, biologicamente activas.
AU454482B2 (en) * 1970-11-05 1974-10-15 Alza Corporation Drug-delivery system

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421178B2 (en) 2011-12-02 2016-08-23 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9421179B2 (en) 2011-12-02 2016-08-23 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9427420B2 (en) 2011-12-02 2016-08-30 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10512621B2 (en) 2011-12-02 2019-12-24 Synchroneuron, Inc. Methods of treating posttraumatic stress disorder with acamprosate salts
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Also Published As

Publication number Publication date
DE2328580A1 (de) 1974-01-10
IL42459A (en) 1976-12-31
JPS4961323A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1974-06-14
IE38151L (en) 1973-12-09
AU5682673A (en) 1974-12-12
FR2187290B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-04-15
OA04931A (fr) 1980-10-31
RO64146A (fr) 1978-11-15
DD109309A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1974-11-05
BE800637A (fr) 1973-12-07
SE395609B (sv) 1977-08-22
IE38151B1 (en) 1978-01-04
IL42459A0 (en) 1973-08-29
HU167947B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-01-28
AU5935773A (en) 1975-02-20
FR2187290A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1974-01-18
PL90109B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-01-31
ZA733897B (en) 1975-01-29
CH582002A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-11-30
GB1428426A (en) 1976-03-17
DD112354A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-04-12
NL7307737A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-12-11
ES415624A3 (es) 1976-10-16

Similar Documents

Publication Publication Date Title
CA1040533A (en) Controlled gastric residence medicament formulation
EP0235718B1 (en) Granule remaining in stomach
US5068110A (en) Stabilization of enteric coated dosage form
Choi et al. Preparation of alginate beads for floating drug delivery system: effects of CO2 gas-forming agents
JP4963767B2 (ja) 制御放出性製剤の製法
EP0662321B1 (en) Method for producing osmosis-controlled tablets avoiding the use of chlorinated hydrocarbons
DK174992B1 (da) Farmaceutisk præparat med langsom frigivelse samt anvendelse af visse additiver i sådanne til opnåelse af langsom frigivelse
Chitnis et al. Bioadhesive polymers-synthesis, evaluation and application in controlled release tablets
HRP980379A2 (en) Sertraline salts and sustained-release dosage forms of sertraline
EA011373B1 (ru) Модифицированное высвобождение фармацевтической композиции
EP0313845A1 (en) Stabilization of enteric coated dosage form
Kono et al. pH-responsive permeability of poly (acrylic acid)—poly (ethylenimine) complex capsule membrane
Ogata et al. Development and evaluation of a new peroral test agent GA-test for assessment of gastric acidity
Shimono et al. Multiparticulate chitosan-dispersed system for drug delivery
Murthy et al. In vitro release characteristics of hard shell capsule products coated with aqueous-and organic-based enteric polymers
Li et al. Water based silicone elastomer controlled release tablet film coating III-Drug Release Mechanisms
WO1997034580A1 (en) Suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid
Gadad et al. Sodium alginate polymeric floating beads for the delivery of cefpodoxime proxetil
EP0999829A1 (en) Solubilized sertraline compositions
Jain et al. Controlled release calcium silicate based floating granular delivery system of ranitidine hydrochloride
WO1992007553A1 (en) Coating or matrix material for medicaments
Vyas et al. Preparation and characterization of microencapsulated gelospheres for controlled oral theophylline delivery
JPS6322014A (ja) 胃内浮遊性持続型カプセル剤
Fites CROSSLINKED POLY (METHYL VINYL ETHER/MALEIC ANHYDRIDE) COPOLYMERS AS CONTROLLED RELEASE PHARMACEUTICAL FILM COATINGS (POLYMETHYL)
Rao et al. Formulation and evaluation of floating microcapsules of cefpodoxime proxetil